How has been the historical performance of Kabra Drugs?

Answer:The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total liabilities rose significantly to 25.23 Cr in March 2025, while total assets also increased to the same amount, indicating a growing but unprofitable operation. Cash flow from operating activities has been negative, with a notable cash inflow from financing activities in March 2025, resulting in a net cash inflow of 18.00 Cr.

Breakdown:
Kabra Drugs has not generated any significant revenue over the years, with net sales consistently at zero from March 2021 to March 2025, except for a slight revenue in March 2019. The total operating income has remained low, with only minor other operating income recorded in earlier years. Total expenditures have escalated, particularly in employee costs and other expenses, leading to increasing operating losses, which reached -1.08 Cr by March 2025. The company's financial position has seen a notable improvement in shareholder's funds, which rose to 24.65 Cr in March 2025, driven by a substantial increase in equity capital. However, total liabilities also surged to 25.23 Cr, reflecting the company's growing financial obligations. Despite these challenges, cash flow from financing activities provided a significant boost, resulting in a net cash inflow of 18.00 Cr in March 2025, although cash flow from operating activities remained negative.